Health technology assessment recommendations. 4 pieces.
The 40 Hz idea is real science, contested in the places that matter, with a pivotal trial due mid-2026. The harder question is the one no one else is asking: if it works, Canada's drug-built access pipeline has nowhere to put a device — and no way to pay for it.
CADTH / INESSSA procedural reform to the reimbursement-review timeline reads like inside baseball. It actually moves the starting gun on every downstream channel event — pCPA negotiation, provincial listing, launch sequencing — earlier by months.
CADTH / INESSS · Specialty distributionA positive reimbursement recommendation for an infused biologic in a renal-autoimmune indication is a discrete event with an outsized channel signature — it establishes a reimbursement pathway where none existed.
CADTH / INESSSA reimburse-with-conditions recommendation for a durvalumab regimen in resectable gastric cancer extends an immunotherapy franchise into the perioperative setting — and the conditions attached are where the channel economics actually get decided.